NEW YORK (GenomeWeb) – VolitionRx announced today that it has received CE marking for two of its blood-based diagnostic assays for colorectal cancer.
The tests, NuQ V001 and NuQ T003, are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features such as histone modifications and variations, DNA methylation patterns, and nucleosome-protein adducts. Last September, the company received CE marking for the NuQ X001S biomarker assay for colorectal cancer detection.
NuQ V001 and NuQ X001S target specific epigenetic cancer signals within the nucleosome, while the NuQ T003 test targets the whole nucleosome. The company said it intends to market a commercial test for colorectal cancer that includes a panel of four to six individual NuQ biomarker assays by the end of 2016.
Clinical testing of additional biomarker assays are ongoing, VolitionRx added. The company also aims to introduce its assays for clinical use in the US, but did not provide a timeframe for market launch.